Abstract

https://ssrn.com/abstract=2411145
 


 



Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech


Aaron S. Kesselheim


Brigham and Women's Hospital/Harvard Medical School; Harvard University - Edmond J. Safra Center for Ethics

March 18, 2011

American Journal of Law and Medicine, Vol. 37, No. 2-3, 2011

Abstract:     
In this article, I first discuss the complex intersection of the drug label and evidence-based medicine. Next, I review the phenomenon of off-label promotion and the controversy that has arisen over FDA regulations related to this field. The controversy over the FDA's authority to regulate off-label promotion can be traced to the essential mismatch between appropriate drug uses and the label. Thus, in the final section, I examine ways to resolve this conflict through changes to the supplemental new drug approval process that can better align restrictions on promotion with knowledge about evidence-based medicine.

Number of Pages in PDF File: 33

Keywords: Prescription drug, FDA, off-label, pharmaceutical marketing

JEL Classification: H51, I11, I18


Open PDF in Browser Download This Paper

Date posted: March 23, 2014  

Suggested Citation

Kesselheim, Aaron S., Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech (March 18, 2011). American Journal of Law and Medicine, Vol. 37, No. 2-3, 2011. Available at SSRN: https://ssrn.com/abstract=2411145

Contact Information

Aaron S. Kesselheim (Contact Author)
Brigham and Women's Hospital/Harvard Medical School ( email )
1620 Tremont St
Suite 3030
Boston, MA 02120
United States
617-278-0930 (Phone)
617-232-8602 (Fax)
HOME PAGE: http://www.drugepi.org/portal
Harvard University - Edmond J. Safra Center for Ethics ( email )
124 Mount Auburn Street
Suite 520N
Cambridge, MA 02138
United States

Feedback to SSRN


Paper statistics
Abstract Views: 607
Downloads: 193
Download Rank: 124,190